-

Agilent Announces Bravo NGS Automated Liquid Handling Platform with On-Deck Thermal Cycler

Enhanced user experience in NGS sample preparation workflow

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of an on-deck thermal cycler (ODTC) that integrates with the Agilent Bravo NGS automated liquid handling platform. The optional ODTC accessory enables the Bravo platform to provide thermal cycling as part of an automated workflow for next-generation sequencing (NGS), end-point PCR, and cell-based applications.

An on-deck thermal cycler is critical in many genomics and molecular biology workflows. This optional accessory enables the Bravo NGS automated liquid handling platform to provide thermal cycling as part of an automated protocol and increases "walk-away" time, providing operators with more freedom to focus on higher-level tasks. This setup is beneficial, particularly for applications such as library preparation and target enrichment steps in NGS workflows.

"The on-deck thermal cycler enables more seamless workflows on Bravo NGS platforms by eliminating multiple touch points where users must remove a microplate from the Bravo deck and place it on an offline, third-party thermal cycling instrument," said Lars Kristiansen, general manager of Agilent’s Automation Solutions Business. "Adding an ODTC to the Bravo platform extends walk-away opportunities, improves performance, and enhances ease-of-use with preprogrammed protocols. This release supports our customers in high-throughput academic and service provider labs who want to improve productivity and reproducibility while maintaining workflow flexibility."

Kevin Kim, head of automation at Avellino Labs, added, "The Bravo with ODTC is a cost-effective and powerful addition to any lab that needs a solution with more walk-away time, smaller footprint, and direct pipetting into the thermal cycler, which is critical for temperature-sensitive assay steps."

Kevin Meldrum, general manager of Agilent’s Integrated Genomics Division, added, “With the ODTC on the Bravo, SureSelect users will have an enhanced experience while taking advantage of the flexibility and quality performance of the SureSelect XT HS2 chemistry.”

Agilent’s modular workflow solutions are designed to integrate easily and work together seamlessly. The Agilent Bravo NGS workstation with ODTC integrates with SureSelect reagents to provide an automated NGS solution that saves time and minimizes the burden of optimizing new automated assays while providing the flexibility to serve a broad range of application needs.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

Naomi Goumillout
Agilent Technologies
+1.781.266.2819
naomi.goumillout@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Naomi Goumillout
Agilent Technologies
+1.781.266.2819
naomi.goumillout@agilent.com

More News From Agilent Technologies Inc.

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. PD-L1 IHC 22C3 pharm...

Agilent Announces Cash Dividend of 25.5 Cents per Share

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22, 2026, to all shareholders of record as of the close of business on March 31, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent’s board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE: A) is a global leader in analyti...

Agilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact Award

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Boehringer Ingelheim has been selected as the winner of Agilent’s inaugural Instrument Trade‑In Impact Award, recognizing exceptional sustainability leadership demonstrated through their participation in Agilent’s trade‑in and buyback program. The annual award honors the global partner that achieves the highest sustainability impact by diverting end‑of‑life laboratory instruments from landfill and con...
Back to Newsroom